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Abstract: T10B9.1A-31/MEDI-500 is a nonmitogenic immunoglobulin M kappa murine 
monoclonal antibody (mAb) directed against the alpha-beta (αβ) heterodimer of the 
T-lymphocyte receptor complex. The hybridoma was first produced by fusing spleen cells from 
BALB/C mice immunized with human peripheral blood T-lymphocytes with SP2/O-Ag14 
mutant myeloma cells. The mAb is produced and purified using multistep ion exchange and 
molecular sieve chromatography protocols. T10B9 has been used successfully to treat acute 
cellular rejection in renal transplantation and as an immunosuppression induction agent in heart 
and simultaneous kidney-pancreas transplantation. Because T10B9 is nonmitogenic and causes 
minimal cytokine release, both treatment of rejection and induction of immunosuppression 
were accomplished with significantly fewer and milder untoward effects (cytokine release 
syndrome) than its comparator OKT3. Since T10B9 is directed against the αβ heterodimer of 
the CD3 epitope, it spares the gamma delta (γδ) region. These gamma delta (γδ) T cells have 
a unique role in the immune response controlling many serious human diseases and perhaps 
facilitating the development of immunologic tolerance. T10B9 has a relatively short duration 
of action, depleting T cells for only 10 to 14 days, unlike the protracted depletion seen with 
thymoglobulin and Campath-1H. There is no B-lymphocyte depletion with T10B9 as there is 
with both of the aforementioned reagents. The lack of prolonged lymphocyte depletion may 
account for less infection observed with T10B9 treatment.
Keywords: T10B9.1A-31, γδ T-cell, monoclonal antibody, Campath-1H, thymoglobulin, OKT3
Introduction
Induction of immunosuppression has become a standard therapy in the United States 
with over 70% of transplantation programs using agents to inhibit the first rejection 
response. The drugs most often used fall into three categories; 1) the interleukin-2 
anti-CD25 selective blocking monoclonal antibodies (mAb) such as basiliximab 
and daclizumab, 2) polyclonal antisera against T-lymphocytes such as rabbit 
antilymphocyte globulin (Thymoglobulin) or 3) the mAb alemtuzumab (Campath-1H) 
which targets T and B cells. The latter two agents have significant effects on B-cells. 
After an initial dose of 30 mg, Campath-1H profoundly suppresses T-cells for up to 
330 days and B-cells for 90 to 150 days. Thymoglobulin significantly suppresses 
T-cells for up to 90 days and has a profound anti-B-cell effect from 15 to 980 days, 
opening many windows for opportunistic infection. (Figure 1).1–11 Clearly there would 
be an advantage for a shorter acting immunosuppression agent which allows T-cell 
recovery, has little or no effect on B cells and, therefore, does not produce profound 
long-term immunosuppression.
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OKT3, the first mAb shown to be effective in treating 
acute cellular rejection, is such a short-acting agent; 
however, it causes significant adverse events including 
those related to its mitogenicity and marked stimulation 
of inflammatory cytokines. T10B9.1A-31/MEDI-500 is a 
short-acting but murine immunoglobulin M kappa (IgMκ) 
mAb that is nonmitogenic in vitro which was developed 
at the University of Kentucky. The purpose of this review 
is to discuss T10B9.1A-31 (T10B9) briefly describing its 
manufacturing process, state its known mechanism of action 
with comparison to OKT3, give a synopsis of T10B9’s 
clinical efficacy, discuss the ability of T10B9 therapy to 
spare γδ T cells which may be important in infection and 
in the development of tolerance; and finally to support the 
thesis that a shorter acting more selective anti-T-lymphocyte 
monoclonal antibody may be a better choice for induction of 
immunosuppression and/or treatment of acute rejection.
Manufacturing process
T10B9.1A-31 is a nonmitogenic IgMκ isotype murine mAb. 
It was produced by fusing spleen cells from BALB/C mice 
immunized with human peripheral blood T-lymphocytes 
with SP2-0/Ag-14 mutant myeloma cells. After preliminary 
screening and cloning three times by limiting dilution, it was 
determined that T10B9 was directed at a monomorphic antigen 
expressed on all post-thymic peripheral blood T-cells, but not 
on other circulating cells or cell precursors. With the help of 
the College of Pharmacy at the University of Kentucky, the 
initial production, purification, and lyophilization of stable 
clinical material was achieved and approved by the US Food 
and Drug Administration (FDA) for T-cell depletion under 
BB-IND-4279. Although the first lot of T10B9 was extracted 
from mouse ascites, subsequent lots were produced in vitro 
and purified with proprietary multistep ion exchange and 
molecular sieve chromatography protocols. The final product 
exhibited 95%–100% protein purity using SDS-PAGE analy-
sis and passed the FDA recommended testing for bacterial, 
fungal, and viral sterility, general safety and pyrogen.12–14
T10B9: Proposed mechanism of action
The therapeutic effectiveness of unmodified murine anti-T 
cell mAb in reversing acute human allograft rejection is 
dependent on the combination of both antibody isotype and 
idiotype interactions with their respective ligands or epitopes. 
The most successful are those specific for the CD3/TCR αβ 
antigen recognition complex.15 The mechanism of OKT3 
action (a murine IgG2a mAb) includes interaction of its Fc 
portion with the high affinity Fc gamma receptor I that is 
present on monocytes. This produces immune activation 
followed by immunosuppression. T10B9, a murine IgMκ 
isotype, is specific for the TCR αβ heterodimer region of the 
CD3 complex, does not react with Fc gamma receptor I and 
thus exhibits reduced immune stimulation and the cytokine 
release syndrome. The TCR αβ specificity of T10B9 is 
defined by its ability to modulate the αβ but not the γδ TCR 
whereas OKT3 modulates both types of CD3 T cell receptors. 
Since T10B9 is directed against the αβ TCR and OKT3 
against the CD3 ε (Epsilon) part of the CD3 complex, they 
differ idiotypically. They are isotypically different as well 
because T10B9 is an IgMκ and OKT3 is an IgG2a murine 
isotype. Therefore, human anti-mouse antibody (HAMA) 
directed against one monoclonal antibody does not neutralize 
the other mAb; they are not cross-reactive. Indeed, patients 
with allograft rejection not responding to therapy with one 
monoclonal antibody have successfully been treated with 
the alternative agent.16 Attempts to fully humanize T10B9 
have been unsuccessful to date; however, there is a chimeric 
mAb which appears to be comparable to the parent compound 
in vitro (JST, personal communication).
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Figure 1 T and B cell response and peak incidence of opportunistic infections after 
thymoglobulin, T10B9 and campath® administration.
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T10B9 induces short-term lymphocyte 
depletion
T10B9 administration results in a rapid decline in lymphoid 
cell counts with respective epitope modulation and 
recovery by day 14. (Figure 2) This is in marked contrast 
to thymoglobulin and Campath-1H and may be one reason 
why infections may occur over many months when either of 
these agents are administered (Figure 1).
T10B9 does not induce proliferation
OKT3 is an established potent T cell mitogen in vivo 
and in vitro whereas studies suggest that T10B9 reduces 
proliferation in peripheral blood mononuclear cells (PBMC). 
In vitro studies were performed to compare the ability of 
T10B9 and OKT3 to induce proliferation and to determine 
whether T10B9 in high concentrations or cross-linked on 
plastic remained incapable of inducing proliferation. The 
response of PBMC from five normal donors was tested 
after day 3 of culture. Soluble T10B9 at doses as high as 
10 mcg/mL were non-mitogenic, while soluble OKT3 is a 
potent mitogen even at low doses.15
Cytokine release
In vitro
In order to compare the ability of both T10B9 and OKT3 
to induce cytokine secretion, the in vitro production of 
cytokines by PBMC from normal donors was determined. 
OKT3 (20 ng/mL) strongly stimulated tumor necrosis 
factor-α (TNFα), interferon-γ (INFγ), interleukin-2 (IL-2), 
and IL-6 release whereas T10B9 (160 ng/mL) failed to induce 
detectible cytokine release from PBMC over a six-day test 
period. In a dose escalation study, T10B9 at doses of 80, 800, 
and 8000 ng/mL failed to induce TNFα release at 24 hours 
after exposure.15
In vivo
Plasma samples from kidney transplantation patients rejecting 
their allograft and undergoing monoclonal MAb antibody 
therapy were tested for cytokine levels. Samples collected 
under informed consent two hours following the first dose 
of either T10B9 or OKT3 underwent ELISA quantitation 
of TNFα, INFγ, IL-2, and IL-6. Of significance, only six of 
30 patients treated with T10B9 exhibited a TNFα response 
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Figure 2 Flow cytometric analysis of lymphoid cells in peripheral blood after administration of T10B9.1A-31, OKT3 or TcR-1 (anti-T cell receptor αβ monoclonal antibody 
[mAB]). There is early T-lymphocyte depletion with re-expression of the cD4 and cD8 epitopes. There is persistent modulation of the cD3/TcR αβ region in these phenotypically 
altered T cells for 10 days while the mABs are being administered with repopulation over 15–40 days.
Drug Design, Development and Therapy 2009:3208
Waid et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
compared to 19 of 23 OKT3-treated patients (P = 0.001). 
Likewise the T10B9 group exhibited a significantly lower 
INFγ response; however, there was no statistical difference 
observed in the IL-2 or IL-6 response (Figure 3).15
Induction of activation antigens
Incubation of PBMC with either T10B9 or OKT3 reveals 
a difference in the in vitro expression of CD69, CD71 
(transferrin receptor), CD25 (P55 Il-2 receptor), and DR 
activation antigens. OKT3 and phytohemagglutinin (PHA) 
induce expression of all activation antigens tested. None 
of the PBMC donors tested exhibited CD25 or DR antigen 
expression following incubation with 10 or 50 µg/mL of 
T10B9. At 50 µg/mL (molar equivalent of 10 mcg/mL 
OKT3) T10B9 did not induce CD69 or CD71 expression.15
induction of apoptosis and iL-2  
release in sup-T13 cells
The ability of OKT3 to induce program cell death (apoptosis) 
has been well documented. Accordingly, the ability of T10B9 
to induce apoptosis in the αβ T-cell line Sup-T13 after 
20 hours of incubation was compared to OKT3 using DNA 
fragmentation analysis and dexamethasone as the positive 
control. Both T10B9 and OKT3 induced the DNA frag-
mentation definitive for apoptosis. The degree of apoptosis 
was quantitated using flow cytometric methods. The media 
control exhibited 18% apoptotic MC540 positive cells. This 
was increased to 38% following T10B9 incubation and 43% 
with OKT3. The secretion of IL-2 by the Sup-T13 cell line 
was also determined following T10B9 or OKT3 stimulation. 
T10B9 proved to be a weaker stimulus for IL-2 than did 
OKT3. However, T10B9 had the ability to generate a cellular 
signal as confirmed by the induction of apoptosis and IL-2 
release in the human T-cell line Sup-T13.15
T10B9 in clinical solid organ 
transplantation
T10B9 has been used successfully to treat acute cellular rejec-
tion in renal transplantation.16–18 In a phase 2 clinical trial of 81 
kidney recipients transplanted at the University of Kentucky, 
T10B9 provided treatment for biopsy proven acute cellular 
rejection equal to that of OKT3 with fewer untoward effects, 
less cytokine release and cytokine nephropathy. Compared 
to OKT3, serum creatinine began falling after two days of 
T10B9 therapy instead of three days and the peak serum 
creatinine rise seen with OKT3 therapy was not present 
(Figure 4). Consistent with its lack of mitogenicity, there was 
significantly less cytokine (TNFα and INFγ) release seen after 
T10B9 administration (Figure 4). Additionally in the T10B9 
treated patients there were fewer serious infections, no PTLD 
and no significant increase in the development of HAMA.18
T10B9 has been successfully used as an immunosup-
pression induction agent in heart transplantation19 and in 
simultaneous kidney–pancreas transplantation.20 T10B9 is 
also used for T-lymphocyte depletion in harvested bone 
marrow prior to haploidentical bone marrow transplantation 
to control graft versus host disease.12,13 Unlike other 
monoclonal and polyclonal antibody preparations, there is no 
experience in treating acute leukemia or aplastic anemia.
T10B9 specificity for αβ TcR  
and for sparing γδ T-cells
T10B9 is specific for the T cell αβ heterodimer region of 
the CD3 epitope. It modulates the αβ but not the γδ TCR 
whereas OKT3 binds to the ε (epsilon) portion of the CD3 
and modulates the entire epitope. Flow cytometry confirms 
the absence of αβ + T cells after both T10B9 and OKT3 
induced modulation; however, after T10B9 administration 
the γδ T-cells persist (Figure 5). The sparing of γδ T cells was 
also confirmed in a multicenter bone marrow depletion trial 
sponsored by the National Heart, Lung and Blood Institute.
Discussion
Since the onset of human organ transplantation, many new 
drugs have been added to improve transplantation outcome. 
In addition to the small molecule shorter acting staples of 
maintenance immunosuppression that include corticoste-
roids, calcineurin inhibitors, purine synthesis and mTOR 
T10B9 is nonmitogenic and causes minimal
cytokine (TNFα and IFNγ) release producing
fewer and milder untoward effects
TNF alpha IFN gamma
500
400
300
200
100
0
1 2
pg
/m
l
T10B9
OKT3
Figure 3 cytokine release in vivo in patients undergoing treatment for acute cellular 
rejection with T10B9 or OKT3.
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inhibitors, biologicals, both monoclonal and polyclonal, have 
been increasingly used for induction of immunosuppression 
and treatment of rejection. The addition of these drugs has 
greatly reduced acute rejection and, in most cases, improved 
long-term graft survival, albeit there is an increased incidence 
of cytopenias, renal insufficiency, neurological complica-
tions, diabetes, hyperlipidemia, infection complications, 
and PTLD.
T10B9 is a novel mAb, with a short duration of activity 
allowing phenotypically altered T lymphocytes to repopu-
late after therapy, has no effect on B lymphocytes, is not 
mitogenic and therefore produces fewer cytokine induced 
side effects and appears to have less propensity toward 
infectious complications. One of the unique characteristics 
of T10B9 is its specificity for only those T lymphocytes 
that express the αβ T-cell receptor (TCR αβ). Generally αβ 
T lymphocytes compose between 95% and 98% of all T-cells 
in the peripheral blood. The remainder are T lymphocytes 
that express only the γδ TCR. In both mice and in humans, 
γδ T lymphocytes are primarily located in proximity to 
epithelial tissues, including the skin, bowel and lung – all 
areas of the body that have early contact with the external 
environment.21,22 These γδ T cells play a major role in host 
first-line defense against bacteria, viruses, and fungi.23–29 An 
important function that differs from the αβ T lymphocyte 
population is the ability of γδ T lymphocytes to recognize and 
respond to such stimuli without the requirement for antigen 
processing and presentation by accessory cells. In this regard 
they contribute to innate immunity, ie, the ability to react 
quickly without requiring prior antigen processing.
Another important feature of their “first-line defense” is 
well documented in the skin. When skin is injured by any 
mechanism, a population of γδ T lymphocytes called den-
dritic epidermal T cells (DETC) responds quickly to injury 
and attach to keratinocytes (the primary cells of the skin). 
These DETC’s secrete pre-growth factors (keratitic growth 
factors 1 and 2 and insulin growth factor 1) that stimulate 
regrowth of the epithelium. This phenomenon has been 
demonstrated in murine lung and is presumed to occur when 
injury occurs to any epithelial tissue. exposure to mild immune 
response. This capacity allows γδ T lymphocytes to control 
a variety of infectious agents, such as Nocardia asteroids, 
Pneumocystis carinii, Mycobacterium bovis, Bordatella per-
tussis, etc.21,22,30 In tissue culture, γδ T cells killed tumor cells 
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Figure 4 T10B9 reverses rejection without the cytokine-induced rise in the serum creatinine seen with OKT3.
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infected with viruses.21,22,24,31 Gamma/delta T lymphocytes 
are also able to modulate inflammatory responses in situ, ie, 
they can directly recognize molecules induced on epithelial 
cells by stress and respond very rapidly. They can also control 
the host immune response and thereby present or limit the 
immunopathology that may occur if there is a sustained 
response to the initial stress. Taken together it is clear that 
the γδ T lymphocytes are actually a critical component of the 
immune system with particular reference to the control of many 
opportunistic infections and the maintenance of homeostasis. 
Currently, the drugs used for immunosuppression induction 
or the treatment of rejection suppress both the αβ and the γδ 
T lymphocytes populations. For example, Thymoglobulin® not 
only suppresses T lymphocytes but also B lymphocytes and 
Campath-1H suppresses T and B lymphocytes and monocytes. 
There have only been two monoclonal antibodies that uniquely 
target the αβ TCR, T10B9 and BMA 031. These two differ by 
the fact that BMA 031 is mitogenic and T10B9 is not. Hence, 
their toxicity profiles are quite different.
Studies have not been performed to demonstrate that 
sparing γδ T lymphocytes makes a difference in solid organ 
transplantation outcome. Increased γδ T cells 100 days 
post-bone marrow transplantation predict a long-term 
favorable outcome. However, the direct evidence that sparing 
γδ T lymphocytes is beneficial to transplant outcome is 
mostly derived from the reported experience using T10B9 
for T cell depletion of donor marrow/stem cells at several 
centers23,33,34 and in solid organ transplantation trials where 
the overall infection rate was only 16.7%.16,17,19 This compares 
favorably to induction with rabbit anti-thymocyte globulin 
(Thymoglobulin®) versus basiliximab (Simulect®) where the 
rate of all infections at 12 months was reportedly 85.8% and 
75.2%, respectively.35
The studies above suggest that γδ T cells appear to be 
important in the control of many serious human diseases, 
most of which unfortunately accompany immunosuppression. 
These cells also appear to have the capability to facilitate 
the development of immunologic tolerance. These are 
features that could be maximized by using T10B9 for both 
transplant immunosuppression induction and for treatment of 
rejection. Parenthetically, T10B9 may be particularly useful 
in composite tissue transplantation. This hypothesis is based 
on the observation of Siemionow and others36–38 that an anti-
rat Mab directed only at the a/b chains of the T-cell receptor 
T10B9 specifically binds with the αβ chains
and spares the γδ chains of the T-cell receptor
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Figure 5 Flow cytometric analysis of peripheral blood T lymphocytes after control (no modulation), OKT3 or T10B9. T10B9 modulation shows a persistent population of γδ 
T cells and an absence of αβ T cells whereas both are absent after OKT3 modulation consistent with modulation of the cD3 epitope.
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was critically important for the development of long term 
tolerance to allogeneic composite transplants. Thus, sparing 
γδ T lymphocytes may provide an important benefit in stem 
cell and solid organ transplantation.
In summary, T10B9 (MEDI-500) is a murine IgMκ 
anti-human T cell monoclonal antibody with reduced immune 
activation potential both in vitro and in vivo. In vitro it does 
not induce DNA synthesis, the expression of activation 
antigens or cytokine release, which is in contrast to OKT3. 
Clinically T10B9 is effective in the reversal of acute renal 
allograft rejection, exhibits lower morbidity and induces 
lower TNFα and INFγ levels after infusion. Finally, it spares 
γδ T lymphocytes which have a unique and important role 
in the immune response; ie, in controlling many serious 
human diseases while inducing αβ T cell immunosuppression 
and perhaps facilitating the development of immunologic 
tolerance. Given the apparent advantages of T10B9 over 
currently available polyclonal and monoclonal reagents, 
would a shorter acting immunosuppressive agent be a better 
therapeutic choice? Is it time for a paradigm shift?
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